

# **Third dose vaccine With BNT162b2 and its response on Long COVID after Breakthrough infections**

**\*Dr. Ashraful Hoque, Assistant Professor, Blood Transfusion, Sheikh Hasina National Institute of Burn & Plastic Surgery, Bangladesh.**

[ashraf.djmc03@gmail.com](mailto:ashraf.djmc03@gmail.com)

**Dr. Md Marufur Rahman PhD Student Department of Oncology and Metabolism, The Medical School, University of Sheffield, UK**

**Dr. Hossain Imam, Assistant Professor, Burn & Plastic Surgery, Sheikh Hasina National Institute of Burn & Plastic Surgery, Bangladesh.**

**Dr. Nurun Nahar, Medical Officer, Dhaka Medical College Hospital, Bangladesh.**

**Dr. Forhad Uddin Hasan Chowdhury, Registrar, Internal Medicine, Dhaka Medical College Hospital, Bangladesh.**

**\*Corresponding author.**

## **Abstract**

**Background:** Breakthrough events are not rare after emerging of Delta variant. On the other hand, long COVID is an unsolved issue where sufferers suffer a lot. Some study has shown that COVID-19 vaccine has improved some clinical and laboratory parameters in long COVID. But what will be the possible measures against long COVID after the breakthrough event is still a burning question.

**Method:** We have observed the third dose by BNT162b2 in a small group (n=20) who were diagnosed as long COVID after breakthrough infections, in Sheikh Hasina National Institute of Burn & Plastic Surgery Institute, Dhaka, Bangladesh. CRP (C-reactive protein) and Anti S1 RBD IgG responses were measured.

## **Result:**

All 20 participants in the study received both dosage of “ChAdOx1-nCoV-19” in between February 2021 to April 2021 and had breakthrough infection in the same or following month which led to long COVID syndrome. They all received a third dose of “BNT162b2”. A before and after 3<sup>rd</sup> dose (14 days after) CRP from participants serum was measured. A Wilcoxon matched paired signed rank test revealed significant (P value <0.05) reduction of inflammatory marker (CRP) after receiving the 3<sup>rd</sup> vaccine dose. Pre and post 3<sup>rd</sup> dose quantitative anti S1-RBD IgG response was measured and compared that revealed significant boosting effect that clearly correlates with the CRP response.

**Conclusion:** Coverage of vaccines all over the world is still not expected level to control this pandemic. WHO has not recommended the use of a third/booster

dose of COVID vaccines. Though our results show some sort of hope for the long COVID in breakthrough events after getting the third dose more study is needed to conclude this issue.

**Key words:** Breakthrough infection, Long COVID, CRP.

## **Introduction:**

From the beginning of COVID-19 spreads around the globe, it is mutating, which means it is acquiring genetic changes. This change has made vaccines difficult to combat and control the pandemic scenario. In the trial results of the vaccine, we have found that it can reduce hospital admission to a great extent. Now data showing on October 21, 2021, 35% of the 519 patients hospitalized with COVID-19 in Massachusetts had been fully vaccinated<sup>1</sup>. Multiple reports have documented that fully vaccinated individuals have become infected; their viral loads may be as high as the levels seen in unvaccinated individuals<sup>2</sup>. Patients with COVID-19 mostly return to baseline after acute infection, but some continue health issues. Throughout the world, what amount of people have been affected by long COVID after acute COVID remains unknown, but published data indicate that about 10- 20% of COVID-19 patients suffer persisting symptoms for weeks to months following acute COVID-19 infection.

According to the Delphi consensus published on 6th October of this year, a post-COVID-19 condition usually occurs in individuals who had a history of probable or confirmed COVID-19 infection, usually 3 months from the onset of COVID-19 with symptoms that last for at least 2 months and cannot be explained by an alternative diagnosis. Brain fog, cognitive dysfunction, shortness of breath, is common presentations. Symptoms may be new-onset

following initial recovery from an acute COVID-19 episode or persist from the initial illness. Symptoms may also fluctuate or relapse over time<sup>3</sup>.

CDC's has defined a breakthrough infection as a COVID case that occurs in someone who is fully vaccinated, meaning 14 or more days after completing the recommended doses of an authorized vaccine.

No specific protocol is yet to be found to treat long COVID. Pharmacological management is still not good enough to cure it. We want to evaluate the role of the third dose of COVID vaccine in patients suffering from long COVID after breakthrough infection.

### **Method:**

This observational study was conducted at Sheikh Hasina National Institute of Burn and Plastic Surgery, Dhaka February 2021 to October 2021. We enrolled 20 participants for our study who received both doses of ChAdOx1-nCoV-19 of the vaccine in the initial rollout of a vaccine in the country (February to April) and had breakthrough infection in the same or following month which led to long COVID syndrome. Participants' demographic data along with past SARS-CoV-2 infection history and existing comorbidities were recorded using a structured questionnaire. Serological testing for CRP was done by Invitrogen CRP Human ELISA kit by ThermoFisher Scientific and antibodies to the RBD of the S1 subunit of the viral spike protein (IgG) was performed from the plasma samples using a commercially available Anti-SARS-CoV-2 ELISA kit(Diasino, China) as per instruction supplied by the manufacturer after getting the third dose by BNT162b2. The study protocol was reviewed and approved by the Institutional Review Committee of the Sheikh Hasina National Institute of Burn and Plastic Surgery, Dhaka (approval memo number: SHNIBPS/July-14(09)). Informed written consent was taken from each participant. Data were summarized by descriptive analysis. Numerical variables are reported as mean

and standard deviation or median and interquartile ranges, as appropriate. Categorical variables are reported as counts and percentages. The analysis was performed in Graphpad Prism 9.0.

## Result:

All 20 participants in the study received both dosage of “ChAdOx1-nCoV-19” in between February 2021 to April 2021 and had breakthrough infection in the same or following month which led to long COVID syndrome. The most commonly reported symptoms were unusual fatigue, palpitation and insomnia. They all received a third dose of “BNT162b2”. A before and after 3<sup>rd</sup> dose (14 days after) CRP from participants serum was measured. A Wilcoxon matched paired signed rank test revealed significant (P value <0.05) reduction of inflammatory marker (CRP) after receiving the 3<sup>rd</sup> vaccine dose (Figure 1).




Figure 1: Comparison of serum CRP level before and after receiving 3<sup>rd</sup> dose of COVID-19 vaccine in individuals with long covid syndrome

Pre and post 3<sup>rd</sup> dose quantitative anti S1-RBD IgG response was measured and compared that revealed significant boosting effect (Figure 2) that clearly correlates with the CRP response shown in Figure 1.




Figure 2: SARS-CoV-2 Anti S1 RBD IgG comparison before and after receiving a 3<sup>rd</sup> dose of COVID-19 vaccine.

### Discussion:

Most COVID-19 vaccines are effective at preventing most infections. But no vaccine is 100% is effective. So breakthrough infections are expected.

On the other hand, long COVID may be driven by long-term tissue damage like brain, lungs, heart, etc caused by inflammation such as autoimmunity, immune dysregulation viral persistence. Female sex, early dyspnoea, prior psychiatric disorders, and specific biomarkers (e.g. D-dimer, CRP, and lymphocyte count)

may associate risk factors may include. More research is needed to establish such risk factors<sup>4</sup>.

One known aspect of long COVID is that similar post viral syndrome was observed with prior human corona virus diseases. For example, symptoms of fatigue, myalgia, and psychiatric impairments have inflicted survivors of Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS) for up to four years<sup>5-9</sup>.

Even at 7-year and 15-year follow-ups, pulmonary and bone radiological complications were still evident among a proportion of SARS survivors who were mostly younger than 40 years<sup>10,11</sup>. A review has proposed that T-cells dysfunction may promote long COVID pathophysiology similarly in autoimmune diseases<sup>12</sup>.

SARS-CoV-2 could make antigen-presenting cells present antigens to auto-reactive T-cells in a process called bystander activation. This is consistent with autopsy examinations of deceased COVID-19 patients showing that infiltrates in the lungs and other organs were enriched with CD8 $\beta$  T cells, one of the crucial mediators of autoimmune reactions<sup>13</sup>.

B-cells may also be involved in long COVID autoimmunity. In a study analysing serum samples from hospitalized COVID-19 patients, antiphospholipid, autoantibodies were detected in 52% of samples, which were further associated with neutrophil hyperactivity and more severe clinical outcomes<sup>14</sup>. Besides, evidence exists that severe COVID-19 causes lymphopenia (i.e. B-cell and T-cell lymphocytes deficiency) that causes hyperinflammation<sup>15,16</sup>. This is because lymphocytes, particularly T-cells, participate in inflammation resolution following infection<sup>17,18</sup>. Meta-analyses have determined lymphopenia and high pro-inflammatory neutrophil count as independent risk factors of COVID-19 severity and mortality<sup>19-21</sup>. Thus, as B-

cell and T-cell lymphocytes are renewed, elevated inflammation from unresolved hyper inflammation may ensue and contribute to longCOVID<sup>22-24</sup>.

Moreover, decreased T-cell and B-cell numbers have been shown to correlate with persistent SARS-CoV-2 shedding, which may further perpetuate chronic immune activation in long COVID<sup>25,26</sup>. Residual inflammation from post-SARS-CoV-2 could lead to long COVID in adults. Raised pro-inflammatory markers (e.g. CRP, IL-6, and D-dimer) and lymphopenia have been associated with long COVID.

Other studies have shown that COVID-19 pulmonary lesions at two-month post-admission were associated with elevated systemic inflammatory biomarkers, such as D-dimer, interleukin-6 (IL-6), and CRP<sup>27,28</sup>.

A study showed, increased D-dimer and CRP levels and decreased lymphocytes were more common in COVID-19 survivors who developed persistent symptoms than their fully recovered counterparts<sup>29</sup>.

Response to infections, liver synthesizes significant quantities of acute-phase proteins (APPs), such as CRP<sup>30,31</sup>. Acute inflammatory protein is a highly sensitive biomarker for inflammation, tissue damage, and infection<sup>32</sup>. Different result has shown that CRP levels are correlated with levels of inflammation<sup>33</sup>. CRP levels can promote phagocytosis and activate the complement system<sup>34</sup>. In other words, CRP binds to microorganisms and promotes their removal through phagocytosis<sup>35</sup>.

Long COVID SOS a survey conducted by UK advocacy group, the University of Exeter, and the University of Kent which showed 57% of participants experienced at least some improvement in symptoms after a vaccine when they were affected by long COVID. Less than 7% have experienced deteriorating



symptoms. Though all vaccines showed benefits they have said mRNA vaccine improved the scenario most.

One of the possible hypotheses behind the improvement after getting the vaccine is, persistent infection causes long-haulers to feel sick, and then the vaccine shot might be helping their immune system finally clear the virus. Another possible theory is that vaccines might rev up a person's immune system and shift the sufferers back into a steady state of equilibrium.

In our study, we have found a dramatic improvement in CRP value which was higher than normal after getting COVID several months back. Their Ct values of rt-PCR were persistently around 36. These changes can be a possibility of immune boost up after the third dose of vaccine which initiates viral clearance from the body. Quantitative assessments of antibodies (IgG) were raised after getting the third dose.

According to these two results with their improvement of symptoms, we hypothesize that the third dose with BNT162b2 might clear the residual viral load as it could halt the ongoing inflammatory process initiated by breakthrough infections.

### **Limitations and Future Suggestions**

This short sample size cannot produce generalizability. Therefore, subsequent clinical studies with larger sample sizes with different age group should be enclosed to confirm our findings.

### **Conclusions:**

The third dose is still not recommended by most the country in the world as well as WHO as vaccines are not sufficient according to the demand of pandemics. Few countries like the USA approved the third dose to combat

against emerging Delta variant. Long COVID is a very notorious condition that has no proper solution to date. From our study, we can hope that the third dose with mRNA vaccine could be an option to control it. More data is needed to conclude this issue.

### **Competing Interest Statement**

The authors have declared no competing interests.

### **Funding Statement**

No external funding was received.

### **Author Declarations**

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

### **Reference:**

1. Massachusetts Department of Public Health.COVID-19 Interactive Data Dashboard.Accessed October 24, 2021.<https://www.mass.gov/infodetails/covid-19-response-reporting#covid-19-interactive-data-dashboard>-
2. Brown CM, Vostok J, Johnson H, et al. Outbreak of SARS-CoV-2 infections, including COVID-19 vaccine breakthrough infections, associated with large public gatherings—Barnstable County, Massachusetts, July 2021. *MMWR Morb Mortal Wkly Rep.* 2021;70(31):1059-1062. doi:10.15585/mmwr.mm7031e23.GBD Long COVID Collaborators.Surviving COVID-19: a global systematic analysis of long COVID disability in 2020. (submitted).
- 3.WHO/2019-nCoV/Post\_COVID-19\_condition/Clinical\_case\_definition/2021.1
4. Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. *Infect Dis (Lond).* 2021 Oct;53(10):737-754. doi: 10.1080/23744235.2021.1924397. Epub 2021 May 22. PMID: 34024217; PMCID: PMC8146298.
5. Das KM, Lee EY, Singh R, et al. Follow-up chest radiographic findings in patients with MERS-CoV after recovery. *Indian J Radiol Imaging.* 2017;27(3):342–349.
- 6.Lee SH, Shin H-S, Park HY, et al. Depression as a Mediator of Chronic Fatigue and Post-Traumatic Stress Symptoms in Middle East Respiratory Syndrome Survivors. *Psychiatry Investigation.* 2019;16(1):59–64.

7. Lam MH. Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors: long-term follow-up. *Arch Intern Med*. 2009;169(22):2142–2147.
8. Ngai JC, Ko FW, Ng SS, et al. The long-term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity, and health status. *Respirology*. 2010;15(3):543–550.
9. Rogers JP, Chesney E, Oliver D, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. *The Lancet Psychiatry*. 2020;7(7):611–627.
10. Zhang P, Li J, Liu H, et al. Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: a 15-year follow-up from a prospective cohort study. *Bone Res*. 2020;8(1):8.
11. Zhao FC, Guo KJ, Li ZR. Osteonecrosis of the femoral head in SARS patients: seven years later. *Eur J Orthop Surg Traumatol*. 2013;23(6):671–677.
12. Karlsson AC, Humbert M, Buggert M. The known unknowns of T cell immunity to COVID. *Sci Immunol*. 2020;5(53):19.
13. Ehrenfeld M, Tincani A, Andreoli L, et al. Covid-19 and autoimmunity. *Autoimmun Rev*. 2020;19(8):102597.
14. Zuo Y, Estes SK, Ali RA, et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. *Sci Transl Med*. 2020;12:eabd3876.
15. Fathi N, Rezaei N. Lymphopenia in COVID-19: therapeutic opportunities. *Cell Biol Int*. 2020;44(9):1792–1797.
16. Tavakolpour S, Rakhshandehroo T, Wei EX, et al. Lymphopenia during the COVID-19 infection: What it shows and what can be learned. *Immunol Lett*. 2020;225:31–32.
17. Cheng Y, Zhao H, Song P, et al. Dynamic changes of lymphocyte counts in adult patients with severe pandemic H1N1 influenza A. *J Infect Public Health*. 2019;12(6):878–883.
18. Kong M, Zhang H, Cao X, et al. Higher level of neutrophil-to-lymphocyte is associated with severe COVID-19. *Epidemiol Infect*. 2020;148:e139.
19. Danwang C, Endomba FT, Nkeck JR, et al. A meta-analysis of potential biomarkers associated with severity of coronavirus disease 2019 (COVID-19). *Biomark Res*. 2020;8(1):37.
20. Malik P, Patel U, Mehta D, et al. Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis. *BMJ Evid Based Med*. 2020. DOI:[10.1136/bmjebm-2020-111536](https://doi.org/10.1136/bmjebm-2020-111536)
21. Ou M, Zhu J, Ji P, et al. Risk factors of severe cases with COVID-19: a meta-analysis. *Epidemiol Infect*. 2020;148:e175.
22. Tavakolpour S, Rakhshandehroo T, Wei EX, et al. Lymphopenia during the COVID-19 infection: What it shows and what can be learned. *Immunol Lett*. 2020;225:31–32.
23. Cheng Y, Zhao H, Song P, et al. Dynamic changes of lymphocyte counts in adult patients with severe pandemic H1N1 influenza A. *J Infect Public Health*. 2019;12(6):878–883.
24. Kong M, Zhang H, Cao X, et al. Higher level of neutrophil-to-lymphocyte is associated with severe COVID-19. *Epidemiol Infect*. 2020;148:e139.

25. Hu F, Chen F, Ou Z, et al. A compromised specific humoral immune response against the SARS-CoV-2 receptor-binding domain is related to viral persistence and periodic shedding in the gastrointestinal tract. *Cell Mol Immunol.* 2020;17(11):1119–1125.
26. Liu B, Han J, Cheng X, et al. Reduced numbers of T cells and B cells correlates with persistent SARS-CoV-2 presence in non-severe COVID-19 patients. *Sci Rep.* 2020;10(1):17718.
27. Marvisi M, Ferrozzi F, Balzarini L, et al. First report on clinical and radiological features of COVID-19 pneumonitis in a Caucasian population: Factors predicting fibrotic evolution. *Int J Infect Dis.* 2020;99:485–488
28. Liao B, Liu Z, Tang L, et al. Longitudinal clinical and radiographic evaluation reveals interleukin-6 as an indicator of persistent pulmonary injury in COVID-19. *Int J Med Sci.* 2021;18(1):29–41
29. Mandal S, Barnett J, Brill SE, et al. Long-COVID': a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID. *Thorax.* 2021;76(4):396–398.
30. R. H. Khalil and N. Al-Humadi, "Types of acute phase reactants and their importance in vaccination," *Biomedical Reports*, vol. 12, no. 4, pp. 143–152, 2020. View at: [Publisher Site](#) | [Google Scholar](#)
31. E. M. Kamal, M. A. Abd El-Hakeem, A. M. El Sayed, and M. M. Ahmed, "Validity of C-reactive protein and procalcitonin in prediction of bacterial infection in patients with liver cirrhosis," *Minia Journal of Medical Research*, vol. 30, no. 3, pp. 124–132. View at: [Google Scholar](#)
32. N. R. Sproston and J. J. Ashworth, "Role of C-reactive protein at sites of inflammation and infection," *Frontiers in Immunology*, vol. 9, p. 754, 2018. View at: [Publisher Site](#) | [Google Scholar](#)
33. T. H. Rainer, C. P. Y. Chan, M. F. Leung et al., "Diagnostic utility of CRP to neutrophin ratio in patients with acute respiratory tract infections," *Journal of Infection*, vol. 58, no. 2, pp. 123–130, 2009. View at: [Publisher Site](#) | [Google Scholar](#)
34. D. Gershov, S. Kim, N. Brot, and K. B. Elkon, "C-reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an anti-inflammatory innate immune response," *Journal of Experimental Medicine*, vol. 192, no. 9, pp. 1353–1364, 2000. View at: [Publisher Site](#) | [Google Scholar](#)
35. P. Pova, J. Pereira, and L. Coelho, "C-reactive protein: structure, synthesis and function," *C-Reactive Protein: New Research*, 2009. View at: [Publisher Site](#) | [Google Scholar](#).